Drug Trial Radar · NCT06337318
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 23, 2024
Primary completion
Mar 31, 2032
Study completion Mar 31, 2032
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Mar 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Conditions
- Classic Follicular Lymphoma
- Follicular Lymphoma With Unusual Cytological Features
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT and/or PET/CT scan
MosunetuzumabBiological
Given SC
Positron Emission TomographyProcedure
Undergo PET/CT scan
RituximabBiological
Given IV
Rituximab and Hyaluronidase HumanBiological
Given SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year milestone progression free survival (PFS)Time frame: From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 3 years
- PFSTime frame: From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 10 years
Locations
289 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
City of Hope Antelope Valley
Lancaster, California · Recruiting
City of Hope at Long Beach Elm
Long Beach, California · Recruiting
Tibor Rubin VA Medical Center
Long Beach, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
City of Hope South Pasadena
South Pasadena, California · Recruiting
Torrance Memorial Physician Network - Cancer Care
Torrance, California · Recruiting
City of Hope Upland
Upland, California · Recruiting
UCI Health - Yorba Linda
Yorba Linda, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
Medical Center of the Rockies
Loveland, Colorado · Recruiting
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Suspended
Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Doral
Doral, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, Florida · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida · Recruiting
Mount Sinai Medical Center
Miami Beach, Florida · Recruiting
Showing 40 of 289 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.